Natalie Mount
Directeur/Membre du Conseil chez Rinri Therapeutics Ltd.
Profil
Natalie joined Abingworth as a Venture Partner in August 2022.
Prior to this Natalie was CEO of Adaptate Biotherapeutics Ltd an Abingworth founded company, focused on developing therapeutic antibodies to drug targets to modulate the activity of gamma delta T cells.
Previously, Natalie was CSO of GammaDelta Therapeutics Ltd.
(also founded by Abingworth) which targeted gamma delta T-cell therapies for use in immunotherapy and was one of the founding team at the Cell and Gene Therapy Catapult serving as its Chief Clinical Officer advising academics and small companies developing advanced therapies.
Natalie’s prior experience also includes 16 years at Pfizer, leading development activities across various therapeutic areas, including cell-based therapies in the Regenerative Medicine Unit.
Natalie has a first-class degree in Natural Sciences from the University of Cambridge and a Ph.D.
from University College, London.
Postes actifs de Natalie Mount
| Sociétés | Poste | Début |
|---|---|---|
Rinri Therapeutics Ltd.
 Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Directeur/Membre du Conseil | - |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Directeur/Membre du Conseil | 10/05/2023 |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Private Equity Investor | 01/08/2022 |
Anciens postes connus de Natalie Mount
| Sociétés | Poste | Fin |
|---|---|---|
Adaptate Biotherapeutics Ltd.
 Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Directeur Général | 26/04/2022 |
| GENSIGHT BIOLOGICS S.A. | Directeur/Membre du Conseil | 16/05/2021 |
| Chimeric Therapeutics Ltd. | Directeur/Membre du Conseil | - |
Cell Therapy Catapult Ltd.
 Cell Therapy Catapult Ltd. BiotechnologyHealth Technology Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Formation de Natalie Mount
| University of Cambridge | Undergraduate Degree |
| University College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Finance |
Cell Therapy Catapult Ltd.
Cell Therapy Catapult Ltd. BiotechnologyHealth Technology Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
| Chimeric Therapeutics Ltd. | Health Technology |
Rinri Therapeutics Ltd.
Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Commercial Services |
Adaptate Biotherapeutics Ltd.
Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Commercial Services |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |
